| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Pete A. Meyers last filed a Form 4 in January 2020, as Chief Financial Officer at EGRX. Pete A. Meyers's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 43,615 shares of EGRX. Net of sales, the EGRX filings show accumulation of 700 shares.
Pete A. Meyers has 7 Form 4 filings on record from May 2017 to January 2020, all as Chief Financial Officer at Eagle Pharmaceuticals (EGRX), 2017–2020.
The 13 reported transactions were 5 option or other derivative awards, 3 tax withholdings, 3 stock awards and 2 open-market purchases.
Counted by filing, the open-market trades come to 2 purchases worth about $44K and no sales.
The largest open-market purchase was 350 shares of EGRX at an average $71.49 on June 12, 2017, about $25K.
Shares as reported in the last Form 4 for each company; the most recent is from January 2020. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.